Post-Translational Modifications Indian Medical PG Practice Questions and MCQs
Practice Indian Medical PG questions for Post-Translational Modifications. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Post-Translational Modifications Indian Medical PG Question 1: Techniques used for protein expression proteomics study include:
- A. PolyAcrylamide Gel Electrophoresis (PAGE)
- B. Gene Expression Analysis (indirectly related to proteomics)
- C. Mass Spectrometry
- D. All of the options (Correct Answer)
Post-Translational Modifications Explanation: ***All of the options***
- All listed techniques—**Polyacrylamide Gel Electrophoresis (PAGE)**, **Gene Expression Analysis**, and **Mass Spectrometry**—are used in protein expression proteomics studies, either directly or indirectly, to analyze and quantify proteins.
- The integration of these various techniques provides a comprehensive approach to understanding protein expression profiles.
*PolyAcrylamide Gel Electrophoresis (PAGE)*
- **PAGE** (including 1D and 2D-PAGE) is a fundamental technique for separating proteins based on their **molecular weight** and **isoelectric point**, which is crucial for visualizing and quantifying expressed proteins.
- It often serves as an initial separation step before more detailed analysis, such as **mass spectrometry**.
*Gene Expression Analysis (indirectly related to proteomics)*
- Although **gene expression analysis** (e.g., using **RT-PCR** or **microarrays**) measures mRNA levels, it is indirectly related to proteomics because mRNA levels often **correlate with protein levels**.
- It provides insights into the **transcriptional regulation** that influences protein expression, complementing direct protein analysis.
*Mass Spectrometry*
- **Mass spectrometry** is a powerful and widely used technique in proteomics for **identifying, quantifying, and characterizing proteins** and peptides by measuring their **mass-to-charge ratio**.
- It can be used for both **discovery proteomics** (identifying novel proteins) and **targeted proteomics** (quantifying specific proteins).
Post-Translational Modifications Indian Medical PG Question 2: Ubiquitin is involved in what process?
- A. Protein folding
- B. Protein degradation (Correct Answer)
- C. Synthesis of nucleic acid
- D. Glycosylation of proteins
Post-Translational Modifications Explanation: ***Protein degradation***
- **Ubiquitin** is a small regulatory protein that attaches to other proteins as a signal, primarily for their **degradation** by the **proteasome**.
- This process, known as **ubiquitination**, marks misfolded, damaged, or no longer needed proteins for targeted destruction.
*Protein folding*
- This process is primarily mediated by **chaperone proteins**, which assist in the correct three-dimensional structuring of polypeptides.
- While ubiquitin can sometimes influence protein folding indirectly by marking misfolded proteins for degradation, its direct role is not in the folding itself.
*Synthesis of nucleic acid*
- The synthesis of **nucleic acids** (DNA and RNA) is carried out by **DNA polymerases** and **RNA polymerases**, respectively.
- Ubiquitin is not involved in the enzymatic processes of replication or transcription.
*Glycosylation of proteins*
- **Glycosylation** is the enzymatic addition of carbohydrate moieties to proteins, typically occurring in the **endoplasmic reticulum** and **Golgi apparatus**.
- This process is crucial for protein function, trafficking, and cell-cell recognition, but ubiquitin has no direct role in it.
Post-Translational Modifications Indian Medical PG Question 3: During eukaryotic protein synthesis, phosphorylation of which of the following is enhanced by insulin?
- A. eIF2
- B. eIF4A
- C. eIF4G
- D. eIF4E (Correct Answer)
Post-Translational Modifications Explanation: ***eIF4E***
- Insulin activates the **mTOR pathway**, which leads to activation of **Mnk1/2 kinases** that phosphorylate eIF4E at **Ser209**.
- This phosphorylation enhances eIF4E's **affinity for the 5' cap structure** and increases **cap-dependent translation initiation** efficiency.
*eIF4G*
- While eIF4G is essential for **eIF4F complex formation**, its phosphorylation is not the primary target enhanced by insulin signaling.
- Insulin's effect on eIF4G is mainly **indirect through 4E-BP1 phosphorylation**, which releases eIF4E to bind eIF4G.
*eIF2*
- **eIF2 phosphorylation** by kinases like **PERK, PKR, and GCN2** inhibits translation initiation during stress conditions.
- This is **opposite to insulin's anabolic effects**, as insulin signaling typically promotes conditions that reduce eIF2 phosphorylation.
*eIF4A*
- eIF4A functions as an **RNA helicase** in the eIF4F complex, unwinding mRNA secondary structures.
- While important for translation, **direct phosphorylation enhancement by insulin** is not a primary mechanism for eIF4A regulation.
Post-Translational Modifications Indian Medical PG Question 4: What is the major site of protein glycosylation?
- A. Ribosome and Golgi body
- B. ER and Ribosome
- C. Ribosome and Cytoplasm
- D. ER and Golgi body (Correct Answer)
Post-Translational Modifications Explanation: ***ER and Golgi body***
- The **endoplasmic reticulum (ER)** is the primary site for **N-linked glycosylation**, where carbohydrates are added to the asparagine residues of nascent proteins.
- The **Golgi apparatus** is crucial for further modification and processing of these N-linked glycans, as well as the site for **O-linked glycosylation**, where sugars are added to serine or threonine residues.
*Ribosome and Golgi body*
- **Ribosomes** are responsible for **protein synthesis (translation)** but do not directly perform glycosylation, which is a post-translational modification.
- While the **Golgi body** is a site of glycosylation, the ribosome's inclusion makes this option incorrect as the ribosome's role precedes glycosylation.
*ER and Ribosome*
- The **ER** is a major site of protein glycosylation, especially N-linked glycosylation.
- However, **ribosomes** are involved in protein synthesis and lack the enzymatic machinery for adding sugar moieties to proteins.
*Ribosome and Cytoplasm*
- **Ribosomes** synthesize proteins, but glycosylation does not occur there.
- The **cytoplasm** is the site for many metabolic pathways, but major protein glycosylation events mostly occur within the ER and Golgi.
Post-Translational Modifications Indian Medical PG Question 5: Recombinant human insulin is made by -
- A. cDNA of pancreatic cell (Correct Answer)
- B. cDNA from any eukaryote cell
- C. Genome of pancreatic cell
- D. Genome of any eukaryote
Post-Translational Modifications Explanation: ***CDNA of pancreatic cell***
- **Recombinant human insulin** is produced using **cDNA** (complementary DNA) synthesized from the **mRNA** of human pancreatic cells, as these cells naturally produce insulin.
- This cDNA ensures that only the **coding sequences** for insulin are used, without introns, making it suitable for expression in prokaryotic hosts like *E. coli*.
*CDNA from any eukaryote cell*
- While insulin is a eukaryotic protein, using cDNA from "any eukaryote cell" would not be specific enough, as only **pancreatic islet beta cells** produce insulin.
- Other eukaryotic cells do not express the insulin gene, so their cDNA would not contain the necessary genetic information.
*Genome of pancreatic cell*
- Although the **genome of a pancreatic cell** contains the insulin gene, it also includes **introns** (non-coding regions) that must be removed through splicing in eukaryotic cells.
- If directly used in prokaryotic systems (like *E. coli*), which lack the machinery to remove introns, it would lead to an incorrect or non-functional protein.
*Genome of any eukaryote*
- Similar to "genome of pancreatic cell," using the **genome of any eukaryote** would be problematic due to the presence of introns and the general lack of the insulin gene in most eukaryotic cells.
- This option combines the disadvantages of non-specificity and the presence of introns that are incompatible with prokaryotic expression systems.
Post-Translational Modifications Indian Medical PG Question 6: With reference to human body's requirement for proteins, they are essential because they are:
1. an important alternative source for energy during specific metabolic states.
2. the primary molecules responsible for maintenance of osmotic pressure within the extracellular compartment.
3. critical for upkeep of cell mediated immune response.
4. vital for the synthesis of certain hormones.
Which of the statements given above are correct?
- A. 2, 3 and 4
- B. 1, 2 and 3
- C. 1, 3 and 4 (Correct Answer)
- D. 1, 2 and 4
Post-Translational Modifications Explanation: ***1, 3 and 4***
- Proteins can be used as an **alternative energy source** during specific metabolic states, such as prolonged fasting or starvation, when carbohydrate and fat stores are depleted, through processes like **gluconeogenesis** and protein catabolism.
- Proteins are critical for the **cell-mediated immune response**, as T-lymphocytes, cytokines, MHC proteins, and various immune mediators are protein-based. Protein-energy malnutrition significantly impairs cell-mediated immunity.
- Many hormones, such as **insulin**, **growth hormone**, **ACTH**, and various **peptide hormones**, are protein-based or derived from amino acids, making proteins vital for hormone synthesis.
*2, 3 and 4*
- Statement 2 is **incorrect** because while proteins (particularly albumin) do contribute to osmotic pressure in the **intravascular compartment**, the statement refers to the "extracellular compartment" broadly, where **electrolytes (especially sodium)** are the primary molecules responsible for osmotic pressure maintenance, not proteins.
- Proteins contribute to **oncotic pressure** (colloid osmotic pressure) specifically, which is distinct from total osmotic pressure.
*1, 2 and 3*
- This option incorrectly includes statement 2, which overstates the role of proteins in osmotic pressure across the entire extracellular compartment.
- It correctly identifies proteins as an energy source and their role in cell-mediated immunity, but fails to include their vital role in **hormone synthesis**.
*1, 2 and 4*
- This option incorrectly includes statement 2 about osmotic pressure in the extracellular compartment.
- It correctly recognizes proteins as an alternative energy source and for hormone synthesis, but omits their critical role in the **cell-mediated immune response**.
Post-Translational Modifications Indian Medical PG Question 7: Thyroid hormone binds to which receptor ?
- A. Membrane
- B. Cytoplasmic
- C. Nuclear (Correct Answer)
- D. None of the options
Post-Translational Modifications Explanation: ***Nuclear***
- Thyroid hormones, being **lipid-soluble**, readily diffuse across the **cell membrane** to bind to receptors located in the nucleus.
- This binding directly influences **gene expression** and protein synthesis, mediating the hormone's effects.
*Membrane*
- Membrane receptors typically bind **water-soluble hormones** (e.g., peptide hormones, catecholamines) that cannot freely cross the cell membrane.
- These interactions usually trigger a **second messenger cascade** within the cell.
*Cytoplasmic*
- While some **steroid hormones** bind to cytoplasmic receptors which then translocate to the nucleus, thyroid hormones bind directly to nuclear receptors.
- Cytoplasmic receptors are located in the **cytosol** before their ligand-induced translocation.
*None of the options*
- This option is incorrect, as thyroid hormones have a specific and well-defined receptor location.
- The direct action on **gene regulation** necessitates a nuclear receptor.
Post-Translational Modifications Indian Medical PG Question 8: ABO antigens are not found in:
- A. Semen
- B. CSF (Correct Answer)
- C. Saliva
- D. Tears
Post-Translational Modifications Explanation: ***CSF***
- ABO antigens are typically expressed on the surface of **red blood cells** and in the secretions of individuals classified as **secretors**.
- **Cerebrospinal fluid (CSF)** is generally devoid of these antigens.
*Semen*
- ABO antigens can be found in **semen**, particularly in individuals who are secretors.
- This is due to the presence of **secreted bodily fluids** containing soluble forms of these antigens.
*Saliva*
- **Saliva** is a well-known source of soluble ABO antigens in secretor individuals.
- The presence of these antigens in saliva is often used in **forensic testing** and blood group determination.
*Tears*
- Similar to other bodily secretions, **tears** can contain soluble ABO antigens in secretor individuals.
- This is part of the general secretion of these antigens into exocrine fluids.
Post-Translational Modifications Indian Medical PG Question 9: A research team is developing a gene therapy approach using CRISPR-Cas9 to correct a point mutation causing sickle cell disease. They must decide between two strategies: (A) correcting the mutation in hematopoietic stem cells ex vivo, or (B) in vivo correction in bone marrow. Considering molecular physiology principles, what is the most significant advantage of strategy A over strategy B?
- A. Strategy A allows for screening and selection of successfully edited cells before transplantation, minimizing off-target effects (Correct Answer)
- B. Strategy A requires lower doses of viral vectors
- C. Strategy A produces faster clinical improvement
- D. Strategy A is less expensive to implement
Post-Translational Modifications Explanation: ***Strategy A allows for screening and selection of successfully edited cells before transplantation, minimizing off-target effects***
- **Ex vivo** correction allows scientists to perform **quality control** by screening the patient's cells for the desired **on-target** modification and ensuring no harmful **off-target** mutations exist.
- This selection process ensures that only **genetically verified** hematopoietic stem cells are re-infused, providing a significant safety and efficacy profile compared to blind **in vivo** delivery.
*Strategy A requires lower doses of viral vectors*
- While the total volume might be smaller, the primary advantage is the **precision** and **safety** of editing, not merely the quantity of the vector used.
- **In vivo** methods actually face greater challenges with **vector distribution** and immune clearance, but this is less critical than the ability to screen cells.
*Strategy A produces faster clinical improvement*
- The **ex vivo** process is time-consuming, involving **cell harvesting**, laboratory editing, and **myeloablative conditioning** before re-infusion.
- Clinical improvement depends on the **engraftment** of edited cells and the turnover of red blood cells, which is not necessarily faster than **in vivo** methods.
*Strategy A is less expensive to implement*
- **Ex vivo** gene therapy is highly expensive due to the need for **specialized laboratory facilities**, intensive cell culture protocols, and prolonged patient **hospitalization**.
- **In vivo** strategies are conceptually cheaper and easier to scale, but currently lack the **safety oversight** provided by laboratory screening.
Post-Translational Modifications Indian Medical PG Question 10: A novel drug is designed to treat a genetic disorder caused by a nonsense mutation in the dystrophin gene. The drug works by allowing the ribosome to skip over the premature stop codon and continue translation. Evaluation of this therapeutic strategy reveals partial restoration of dystrophin protein with 60% of normal length but sufficient function. What is the most critical molecular consideration in determining if this approach will be clinically beneficial?
- A. Whether the drug prevents degradation of dystrophin mRNA
- B. Whether the drug enhances ribosomal binding to the start codon
- C. Whether the drug increases transcription of the dystrophin gene
- D. Whether the truncated protein retains the actin-binding domain and maintains membrane stability (Correct Answer)
Post-Translational Modifications Explanation: ***Whether the truncated protein retains the actin-binding domain and maintains membrane stability***
- For a truncated **dystrophin** protein to be clinically effective, it must preserve the functional linkage between the **actin cytoskeleton** and the **extracellular matrix**.
- This is the fundamental mechanism behind converting a severe **Duchenne** phenotype into a milder **Becker** muscular dystrophy phenotype through **read-through** or exon-skipping therapies.
*Whether the drug prevents degradation of dystrophin mRNA*
- While **nonsense-mediated decay (NMD)** can reduce mRNA levels in nonsense mutations, preventing degradation is useless if the resulting translation still produces a non-functional protein.
- The primary goal of read-through therapy is the quality and **functional domains** of the protein produced, rather than just the quantity of mRNA present.
*Whether the drug enhances ribosomal binding to the start codon*
- Enhancing **ribosomal binding** to the **start codon** (AUG) might increase the initiation of translation but does not address the premature stop codon issue.
- Clinical benefit depends on the ribosome's ability to bypass the **premature termination codon (PTC)**, not the efficiency of initial binding.
*Whether the drug increases transcription of the dystrophin gene*
- Increasing **transcription** would only result in more mutated mRNA transcripts, which would still terminate at the **premature stop codon**.
- Without a mechanism to ensure a functional protein product, simply increasing **gene expression** does not mitigate the mechanical instability of the muscle cell membrane.
More Post-Translational Modifications Indian Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
oka